Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1961 1
1975 1
1982 1
1989 1
1990 1
1991 3
1992 3
1993 1
1994 5
1995 10
1996 7
1997 7
1998 9
1999 8
2000 17
2001 13
2002 17
2003 12
2004 171
2005 18
2006 40
2007 40
2008 51
2009 76
2010 94
2011 123
2012 157
2013 135
2014 130
2015 177
2016 163
2017 162
2018 174
2019 158
2020 193
2021 206
2022 245
2023 233
2024 269
2025 216
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,886 results

Results by year

Filters applied: . Clear all
Page 1
ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion.
Deng S, Zhang Y, Wang H, Liang W, Xie L, Li N, Fang Y, Wang Y, Liu J, Chi H, Sun Y, Ye R, Shan L, Shi J, Shen Z, Wang Y, Wang S, Brosseau JP, Wang F, Liu G, Quan Y, Xu J. Deng S, et al. Among authors: shan l. Cell. 2024 Apr 25;187(9):2305-2323.e33. doi: 10.1016/j.cell.2024.03.019. Epub 2024 Apr 12. Cell. 2024. PMID: 38614099 Free article.
Silencing of SIRPα enhances the antitumor efficacy of CAR-M in solid tumors.
Zhang H, Huo Y, Zheng W, Li P, Li H, Zhang L, Sa L, He Y, Zhao Z, Shi C, Shan L, Yang A, Wang T. Zhang H, et al. Among authors: shan l. Cell Mol Immunol. 2024 Nov;21(11):1335-1349. doi: 10.1038/s41423-024-01220-3. Epub 2024 Oct 8. Cell Mol Immunol. 2024. PMID: 39379603 Free PMC article.
Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial.
Pan J, Tan Y, Shan L, Seery S, Deng B, Ling Z, Xu J, Duan J, Wang Z, Wang K, Yu X, Zheng Q, Xu X, Hu G, Tan T, Yuan Y, Tian Z, Yan F, Han Y, Zhang J, Feng X. Pan J, et al. Among authors: shan l. Nat Med. 2025 Jan;31(1):126-136. doi: 10.1038/s41591-024-03282-2. Epub 2024 Oct 1. Nat Med. 2025. PMID: 39354195 Clinical Trial.
C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial.
Zuo S, Li C, Sun X, Deng B, Zhang Y, Han Y, Ling Z, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Zong J, Tian Z, Shan L, Tang K, Huang H, Song Y, Niu Q, Zhou D, Feng S, Han Z, Wang G, Wu T, Pan J, Feng X. Zuo S, et al. Among authors: shan l. Nat Commun. 2024 Jul 22;15(1):6155. doi: 10.1038/s41467-024-50485-9. Nat Commun. 2024. PMID: 39039086 Free PMC article. Clinical Trial.
1-(2'-Deoxy-2'-[18F]fluoro-β-d-arabinofuranosyl)-5-iodocytosine.
Shan L. Shan L. 2012 Mar 19 [updated 2012 Apr 11]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2012 Mar 19 [updated 2012 Apr 11]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 22514809 Free Books & Documents. Review.
2,886 results